Oracle may be closing in on $30B purchase of EMR giant Cerner

Matt O'Connor | | Health Exec | Digital Transformation
Cerner at HIMSS19

Cerner showcases several of its products at the HIMSS 2019 conference in Orlando, Florida. 

Oracle, one of the largest software companies in the world, is closing in on the purchase of Cerner for an estimated $30 billion, the Wall Street Journal reported Thursday.

People familiar with the matter said negotiations could be finalized soon and would be considered the largest ever for Oracle. The move would push the software giant further into the cloud and healthcare spaces as it seeks to compete with the likes of Amazon and Microsoft.

Kansas City, Missouri-based Cerner currently has a market cap of about $23 billion and recently hired former Geisinger CEO and Google Health leader David Feinberg as its chief executive officer.

Oracle, meanwhile, boasts a value of more than $280 billion, making it the second-biggest software venture in the world by revenue and market capitalization.

A deal for Cerner would surpass Oracle’s largest transaction to date, approximately $10 billion it paid to buy enterprise-software firm PeopleSoft in 2005. It also acquired NetSuite, a cloud provider, for $9 billion in 2016.

Read the full story below.

Oracle in Talks to Buy Cerner

""
Matt O'Connor

Matt joined Chicago’s TriMed team in 2018 covering all areas of health imaging after two years reporting on the hospital field. He holds a bachelor’s in English from UIC, and enjoys a good cup of coffee and an interesting documentary.

Related Content

To tell or not to tell: Do patients really need to know who—or what—writes their doctor’s notes?
5 ways AI can help make healthcare more affordable for everyone
HIMSS survey report: Beware insider threats to cybersecurity involving AI
Primary care is primed for AI. But is AI aligned with primary care?
Machine learning vs. bodily pain: 5 points of promise and challenge
Generative AI isn’t changing everything for patients and providers—but it’s not leaving much unaffected, either

Around the web

Cardiovascular Business
Boston Scientific enters renal denervation market with acquisition worth up to $540M

Boston Scientific has announced another significant M&A deal, scooping up an Israeli medtech company focused on RDN technology. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
FDA announces catheter recall for Johnson & Johnson PFA system due to stroke risk

The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.